Published in J Biol Chem on April 07, 2003
Gamma' fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem (2010) 1.80
Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains. Blood (2005) 1.64
Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS One (2010) 1.22
Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA (2009) 0.98
Long range communication between exosites 1 and 2 modulates thrombin function. J Biol Chem (2009) 0.94
Association between γ' fibrinogen levels and inflammation. Thromb Haemost (2010) 0.91
Fibrin-induced skin fibrosis in mice deficient in tissue plasminogen activator. Am J Pathol (2005) 0.89
Biophysical investigation of GpIbalpha binding to thrombin anion binding exosite II. Biochemistry (2009) 0.85
Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. J Biol Chem (2013) 0.84
Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem (2011) 0.84
Thrombin-dependent MMP-2 activity is regulated by heparan sulfate. J Biol Chem (2010) 0.79
Role of electrostatic interactions in binding of thrombin to the fibrinogen γ' chain. Biochemistry (2012) 0.76
Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. PLoS One (2016) 0.75
Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin. J Biol Chem (2014) 0.75
Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen. J Biol Chem (2013) 0.75
Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates. Biophys J (2017) 0.75
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med (2006) 1.78
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation (2014) 1.64
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood (2011) 1.51
Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49
Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood (2011) 1.48
New anticoagulants. Circulation (2010) 1.48
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Strain history dependence of the nonlinear stress response of fibrin and collagen networks. Proc Natl Acad Sci U S A (2013) 1.35
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol (2008) 1.21
Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem (2001) 1.21
Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol (2009) 1.19
Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care (2012) 1.18
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost (2013) 1.15
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost (2010) 1.14
New anticoagulants. Blood (2004) 1.13
Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem (2007) 1.13
G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008) 1.10
Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.08
Oral direct factor Xa inhibitors. Circ Res (2012) 1.08
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.07
Coagulation assays. Circulation (2005) 1.05
Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest (2014) 1.05
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood (2014) 1.05
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood (2008) 1.03
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. J Biol Chem (2006) 1.01
Hypercoagulable states. Clin Chest Med (2010) 1.00
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc (2013) 0.94
Long range communication between exosites 1 and 2 modulates thrombin function. J Biol Chem (2009) 0.94
Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. J Biol Chem (2001) 0.94
Thromboprophylaxis in surgical patients. Can J Surg (2003) 0.91
Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem (2003) 0.90
New and emerging anticoagulant therapies for venous thromboembolism. Curr Treat Options Cardiovasc Med (2010) 0.90
Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thromb Haemost (2008) 0.89
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis (2013) 0.89
Update on heparin: what do we need to know? J Thromb Thrombolysis (2010) 0.89
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost (2015) 0.89
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res (2003) 0.88
Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. J Thromb Thrombolysis (2009) 0.88
Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. J Biol Chem (2010) 0.87
Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS (2014) 0.87
The status of new anticoagulants. Br J Haematol (2006) 0.86
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol (2005) 0.86
Zinc: an important cofactor in haemostasis and thrombosis. Thromb Haemost (2013) 0.85
A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem (2011) 0.85
A replacement for warfarin: the search continues. Circulation (2007) 0.85
Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin. J Biol Chem (2013) 0.84
Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol (2012) 0.84
Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain. J Biol Chem (2011) 0.84
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater (2012) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. Shock (2015) 0.83
Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2016) 0.83
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost (2004) 0.83